NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update
Go back to NCCN Recommends ctDNA-MRD Testing Using Signatera™ Technology in Landmark Bladder Cancer Guideline Update| (NASDAQ: NTRA) | Delayed: 328.18 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $328.18 | 52 Week High | $13.80 | |||
| Open | $328.18 | 52 Week Low | $6.52 | |||
| Day High | $328.18 | P/E | N/A | |||
| Day Low | $328.18 | EPS | $0.00 | |||
| Volume | 696 | |||||
